Elicio Therapeutics Q2 net loss widens

Overview

• Elicio Q2 net loss widens to $10.6 mln from $7.2 mln in 2024

• R&D expenses decrease due to reduced clinical trial manufacturing costs

• Co secures $10 mln in additional financing, extending cash runway into Q1 2026

• IDMC recommends continuation of ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications to final analysis

Outlook

• Company expects event-driven final analysis focused on disease-free survival in Q4 2025

• Current cash supports operations into Q1 2026

Result Drivers

• R&D EXPENSES - Decrease in R&D expenses due to reduced clinical trial manufacturing costs

• FINANCING - Secured $10 mln financing to extend cash runway into Q1 2026

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Elicio Therapeutics Inc is $12.50, about 25% above its August 6 closing price of $9.37

Press Release: ID:nGNX8pGrz7